Hyloris Pharmaceuticals SA (0AB6.L)
- Globe Newswire
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted to €4.4 millionStronger growth expected in 2024 of both sales and gross margin, mainly fueled by the recent launch in the U.S. of Maxigesic® IV and Podofilox gel, the global roll out of Maxigesic IV® and commercial dealsIncreased operating R&D expenses while net operating cash outflow remained stable versus 2022Significant R&D progress including clinical and regulatory achievements with
- Globe Newswire
Communication at the request of the FSMA on the transactions with Qliniq
Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY 2023) financial statements following a correction of a non-cash error in the accounting treatment of the transactions with Qliniq announced on 20 January 2023HY-088 and HY-038 considered as a non-monetary exchange under IAS 38.45 in 2023No impact on the cash flow and cash position Liège, Belgium – 14 March 2023 – 07:00AM CET – Regulated Information – Inside informaition - Hyloris P
- GlobeNewswire
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET. Following the release, the company will host a live webcast to discuss 2023 results and the outlook for 2024. Participants will have a ch
